Advertisement

Topics

Pfizer still mum on BD, frustrated by biosimilar market

06:15 EDT 1 Aug 2017 | BioPharmaDive

Second quarter earnings for the big pharma were uneventful, but commentary on business development and the biosimilar market were illuminating.

Original Article: Pfizer still mum on BD, frustrated by biosimilar market

NEXT ARTICLE

More From BioPortfolio on "Pfizer still mum on BD, frustrated by biosimilar market"

Quick Search
Advertisement
 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...